Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, March 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

policy: 1 policy source
twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 63 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Ninlaro for Multiple Myeloma (2nd-beyond) – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Jul 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.